CliffBio
biologic

Trumenba

Meningococcal Group B Vaccine

Loss of exclusivity—loss of exclusivity
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand nameTrumenba
Active ingredientMeningococcal Group B Vaccine
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
Marketing statusRx

More from Wyeth

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.